Integrated safety analysis of umbralisib, a dual PI3Kδ/CK1ε inhibitor, in relapsed/refractory lymphoid malignancies.

Journal Article (Journal Article)

Phosphoinositide 3-kinase-δ (PI3Kδ) inhibitors are active in lymphoid malignancies, although associated toxicities can limit their use. Umbralisib is a dual inhibitor of PI3Kδ and casein kinase-1ε (CK1ε). This study analyzed integrated comprehensive toxicity data from 4 open-label, phase 1 and 2 studies that included 371 adult patients (median age, 67 years) with relapsed/refractory non-Hodgkin lymphoma (follicular lymphoma [n = 147]; marginal zone lymphoma [n = 82]; diffuse large B-cell lymphoma/mantle cell lymphoma [n = 74]; chronic lymphocytic leukemia [n = 43]; and other tumor types [n = 25]) who were treated with the recommended phase 2 dose of umbralisib 800 mg or higher once daily. At data cutoff, median duration of umbralisib treatment was 5.9 months (range, 0.1-75.1 months), and 107 patients (28.8%) received umbralisib for ≥12 months. Any-grade treatment-emergent adverse events (AEs) occurred in 366 (98.7%) of 371 patients, with the most frequent being diarrhea (52.3%), nausea (41.5%), and fatigue (31.8%). Grade 3 or higher treatment-emergent AEs occurred in 189 (50.9%) of 371 patients and included neutropenia (11.3%), diarrhea (7.3%), and increased aminotransferase levels (5.7%). Treatment-emergent serious AEs occurred in 95 (25.6%) of 371 patients. AEs of special interest were limited and included pneumonia (29 of 371 [7.8%]), noninfectious colitis (9 of 371 [2.4%]), and pneumonitis (4 of 371 [1.1%]). AEs led to discontinuation of umbralisib in 51 patients (13.7%). Four patients (1.1%) died of AEs, none of which was deemed related to umbralisib. No cumulative toxicities were reported. The favorable long-term tolerability profile and low rates of immune-mediated toxicities support the potential use of umbralisib for the benefit of a broad population of patients with lymphoid malignancies.

Full Text

Duke Authors

Cited Authors

  • Davids, MS; O'Connor, OA; Jurczak, W; Samaniego, F; Fenske, TS; Zinzani, PL; Patel, MR; Ghosh, N; Cheson, BD; Derenzini, E; Brander, DM; Reeves, JA; Knopińska-Posłuszny, W; Allan, JN; Phillips, T; Caimi, PF; Lech-Maranda, E; Burke, JM; Agajanian, R; Pettengell, R; Leslie, LA; Cheah, CY; Fonseca, G; Essell, J; Chavez, JC; Pagel, JM; Sharman, JP; Hsu, Y; Miskin, HP; Sportelli, P; Weiss, MS; Flinn, IW

Published Date

  • December 14, 2021

Published In

  • Blood Adv

Volume / Issue

  • 5 / 23

Start / End Page

  • 5332 - 5343

PubMed ID

  • 34547767

Pubmed Central ID

  • PMC9153017

Electronic International Standard Serial Number (EISSN)

  • 2473-9537

Digital Object Identifier (DOI)

  • 10.1182/bloodadvances.2021005132

Language

  • eng

Conference Location

  • United States